US FDA Extends Race/Ethnicity Clinical Data Collection Guidelines To Observational Studies
Executive Summary
However, new draft guidance expressly does not address diversity action plans required under Food and Drug Omnibus Reform Act; initial guidance on these plans was due in December 2023 but has yet to be released.